SECURE A Non-Interventional Long-Term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia?) for Crohn's Disease
Principal Investigator (?)
The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry''s target enrollment is 3045 patients and it''s objective is to monitor patients for approximately 8 years.
UCB Pharma, Inc.
Available at the following location(s)
- Decision-Making Help
- Medical Records & Release Forms
- Health Encyclopedia
- Clinical Trials
- Lifestyle Changes
- Emmi® Patient Education
- Frequently Asked Questions on Scabies